Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2021-01-26 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2020年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2020 annual performance forecast (业绩预告) for 瑞康医药集团股份有限公司, covering the full fiscal year from January 1, 2020 to December 31, 2020. It provides estimated net profit and earnings per share figures, explicitly states that the data is preliminary and unaudited, and mentions that the final audited figures will be disclosed in the 2020 annual report. The document is short (971 characters) and serves as a performance forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and analysis. Therefore, the correct classification is Earnings Release (ER). FY 2020
2021-01-26 Chinese
关于向关联方控制的山东乐康金岳实业有限公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding an investment transaction where 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.) plans to increase capital in a related party controlled company, 山东乐康金岳实业有限公司 (Shandong Lekang Jinyue Industrial Co., Ltd.). It includes comprehensive information about the transaction, the parties involved, the valuation and pricing basis, audited financial data of the target company, and the impact on the listed company. The document also contains independent directors' opinions and risk disclosures. The content is typical of a capital or financing update related to a significant related-party transaction and investment in a subsidiary. It is not a full annual or interim report, audit report, earnings release, or other types of filings. The document length (13,004 characters) and detailed financial and transaction data confirm it is a substantive announcement rather than a brief notice or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-01-26 Chinese
第四届监事会第十一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at the 11th meeting of the 4th Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It details the approval of a related-party capital increase transaction involving a controlled company. The document includes voting results and confirms compliance with relevant laws and regulations. The length is short (1249 characters), and it is an announcement of a board/management decision rather than a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG).
2021-01-26 Chinese
第四届董事会第十一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.). It details the approval of a related-party transaction involving capital increase in a controlled company. The document includes voting results, mentions compliance with company law and stock exchange listing rules, and states that the resolution was passed. The document length is short (1395 characters) and it is an announcement of a board decision rather than a full report or financial statement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-01-26 Chinese
独立董事关于向关联方的企业增资的关联交易事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing a prior approval opinion on a related-party transaction involving capital increase to an affiliated enterprise. It references compliance with regulatory guidelines and internal company rules, and it is a formal opinion rather than a financial report or announcement of voting results. The document length is short (708 characters) and it does not contain financial statements or data. It is not an annual report, audit report, earnings release, or any other financial report type. It is also not a voting result announcement or a management change notice. The content fits best under Regulatory Filings (RNS) as it is a regulatory compliance document related to corporate governance and related-party transactions but does not fit other specific categories.
2021-01-26 Chinese
与关联方签署总代理框架协议暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 瑞康医药集团股份有限公司 regarding the signing of a general agency framework agreement with related parties, constituting a related-party transaction. It details the transaction overview, related parties' information, agreement contents, transaction purpose, financial data, independent directors' opinions, and board meeting resolutions. The document is an announcement of a related-party transaction and does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a related-party transaction that does not fit other specific categories.
2020-12-11 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.